Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.17p
   
  • Change Today:
      0.000p
  • 52 Week High: 0.26
  • 52 Week Low: 0.17
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 900,933
  • Market Cap: £3.65m

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart (28-09-2026)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 1.3  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) 1.47p 2.5 n/a n/a n/a 0.0%
31-Mar-24 0.40 (3.57) (1.14)p n/a n/a n/a n/a 0.0%
31-Mar-25 n/a (2.09) (0.36)p n/a n/a n/a n/a 0.0%
31-Mar-26 n/a (3.57) (0.16)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Final Results for the year ended 31 March 2026 28-Sep-2026 07:00 RNS
Notice of Results and Investor Presentation 14-Sep-2026 07:00 RNS
Holding(s) in Company 11-Sep-2026 15:52 RNS

Theracryf ShareCast News

Theracryf upbeat on initial toxicology data from... 14-May-2026 ShareCast
TheraCryf manufactures over 2kg of Ox-1 receptor... 20-Apr-2026 ShareCast
TheraCryf lead Ox-1 programme advances to final ... 23-Mar-2026 ShareCast

Latest Theracryf Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.17p
Change Today 0.000p
% Change 0.00 %
52 Week High 0.26
52 Week Low 0.17
Volume 900,933
Shares Issued 2,148.96m
Market Cap £3.65m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average13.79% above the market average
90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average90.24% above the sector average
Price Trend
86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average86.93% below the market average
72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average72.73% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for 28-Sep-2026

Time Volume / Share Price
14:00 400,000 @ 0.18p
14:00 400,000 @ 0.18p
13:22 500,000 @ 0.18p
10:37 239 @ 0.18p
10:37 694 @ 0.18p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page